European regulators are to review Sandoz's biosimilars of the inflammatory diseases medicines, Humira and Remicade, as competition intensifies to take market share from big-selling monoclonal anti ...

The tumor necrosis factor inhibitors Enbrel (etanercept), Humira (adalimumab), Remicade (infliximab) and Cimzia (certolizumab pegol) are being investigated by the US Food and Drug Administration ...